The invention discloses a new DGAT1 inhibitor which comprises a compound shown as a formula (I) in the specification and pharmaceutically-acceptable salts thereof, a preparation method thereof, a pharmaceutical composition, and application of the inhibitor and the pharmaceutical composition to prepare medicine for preventing and treating familial chylomicronemia syndrome (FCS), adiposis, hyperlipoproteinemia and hypertriglyceridemia.
